Scientific Articles

EGFRvIII

• ASCO 2009 Poster - Epidermal growth factor receptor variant III-targeted vaccine in GBM
• Bruce Goldman. An Injection of Hope, Journal of Life Sciences. 2007 1: 56-62.
• ASCO 2007 Poster - Temozolomide as a Vaccine Adjuvant in GBM
• Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncology.. 2007 Jun 1;25(16):2288-94.
• Bruce Goldman. Taming a Mutinous Mutant: An Errant Receptor Becomes a Prime Cancer Target J. Natl. Cancer Inst. 2007 99: 504-505
• Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 2003 9(11):4247-54.
• Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr. Cancer Drug Targets. 2002 2(2):91-102
• C-T Kuan, CJ Wikstrand and DD Bigner. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocrine-Related Cancer. 2001 8:83-96.
• Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. 1996 13(1):85-96.

Antibody-Drug Conjugate Programs

• SABCS 2009 Poster - A Phase 1/2 Study of CR011-vcMMAE (CDX-011), an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer
• ASCO 2009 Poster - A Phase 1/2 Study of CDX-011, an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer
• ASCO 2009 Poster - Pharmacokinetics of CDX-011, an Antibody-Drug Conjugate, in a Phase 1 Study of Patients with Advanced Melanoma
• ASCO 2009 Poster - A Phase 1/2 Study of CDX-011, an Antibody-Drug Conjugate Targeting Glycoprotein NMB in Patients with Advanced Melanoma
• iSBTc 2008 Poster - Phase 1/2 Study of CDX-011, an Antibody-Drug Conjugate Targeting GPNMB, for the Treatment of Patients with Advanced Melanoma.
• ASCO 2008 Poster - A Phase 1/2 Study of CDX-011, an Antibody-Drug Conjugate, in Patients with Unresectable Stage III or Stage IV Melanoma
• AACR 2007 Poster - Phase 1 Pharmacokinetic Study of CDX-011, an Antibody Toxin Conjugate Drug, in Patients with Unresectable Stage III/IV Melanoma
• Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, Hahne WF, Senter PD, Jeffers ME, Lichenstein HS, LaRochelle WJ. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35.
• AACR 2006 Poster - CDX-014, a potent fully human monoclonal antibody-monomethylauristatin E-conjugated drug targeting ovarian and renal cell carcinoma
• Mesri M, Smithson G, Ghatpande A, Chapoval A, Shenoy S, Boldog F, Hackett C, Pena CE, Burgess C, Bendele A, Shimkets RA, Starling GC. Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins. Int Immunol. 2006 Mar;18(3):473-84.
• Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res. 2006 Feb 15;12(4):1373-82.

APC Targeting Vaccine Reviews

• Francisca A. Neethling, Venky Ramakrishna, Tibor Keler, Rico Buchli, Jon A. Weidanz; Assessing vaccine potency using TCRmimic Antibodies, Vaccine. vol. 26 (14) 2008
• Keler T, He L, Ramakrishna V, Champion B., Antibody-targeted vaccines. Oncogene. 2007 May 28;26(25):3758-67.

APC Targeting: Mannose Receptor

• iSBTc 2009 Poster - A Clinical Study Combining Multiple Immune Modulators and an APC-Targeted hCG-β Vaccine (CDX-1307)
• ASCO 2009 Presentation – Phase 1 clinical results of an APC-targeted hCG-β vaccine (CDX-1307) with TLR agonists
• iSBTc 2008 Poster - Phase 1 Clinical Results Comparing Local and Systemic Administration of an APC-Targeted Cancer Vaccine
• ASCO 2007 Poster – APC-targeted hCG-β vaccine for Cancer Therapy
• Venky Ramakrishna*, John P Vasilakos, Joseph D Tario Jr, Marc A Berger, Paul K Wallace and Tibor Keler. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. Journal of Translational Medicine. 2007, 5:5
• Li-Zhen He, Andrea Crocker, Janine Lee, Jose Mendoza-Ramirez, Xi-Tao Wang, Laura A. Vitale, Thomas O’Neill, Chris Petromilli, Hui-Fen Zhang, Joe Lopez, Dan Rohrer, Tibor Keler, and Raphael Clynes. Antigenic Targeting of the Human Mannose Receptor Induces Tumor Immunity. The Journal of Immunology, 2007, 178: 6259 – 6267.
• He L, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL, Valkova-Vachnova M, Arunakumari A, Treml JF, Goldstein J, Wallace PK, Keler T and Endres MJ. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin γ. Clinical Cancer Research. 2004 10 (6).
• Keler T, Ramakrishna V, Fanger MW. Mannose receptor-targeted vaccines. Expert Opin Biol Ther. 2004 4(12):1953-62.
• Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith P, Jones CL, He L, Goldstein J, Wallace PK, Keler T, and Endres MJ. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. 2004 172(5):2845-52.
• Wallace P. K., K. Y. Tsang, J. Goldstein, P. Correale, T. M. Jarry, J. Schlom, P. M. Guyre, M. S. Ernstoff, and M. W. Fanger. Exogenous antigen targeted to FcγRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods. 2001 248:183.
• Guyre CA, Keler T, Swink SL, Vitale LA, Graziano RF, Fanger MW. Receptor modulation by FcγRI-specific fusion proteins is dependent on receptor number and modified by IgG. J. Immunol. 2000 167:6303-11.
• Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van de Winkel JGJ, Deo YM, et al. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J. Immunol. 2000 165(12):6738-42.
• van Vugt MJ, Kleijmeer MJ, Keler T, Zeelenberg I, van Dijk MA, Geuze HJ, et al. The FcγRIa (CD64) ligand binding chain triggers MHC class II antigen presentation independently of its associated FcR γ-chain. Blood. 1999 94(2):808-17
• Fanger, N. A., D. Voigtlaender, C. Liu, S. Swink, K. Wardwell, J. Fisher, R. F. Graziano, L. C. Pfefferkorn, and P. M. Guyre. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor FcγRI (CD64) expressed on human Blood DCs. J. Immunol. 1997 158:3090.
• Wallace PK, Keler T, Guyre PM, Fanger MW. FcγRI blockade and modulation for immunotherapy. Cancer Immunol. Immunotherapy. 1997 45:137-141.
• Heijnen, I. A., M. J. van Vugt, N. A. Fanger, R. F. Graziano, T. P. de Wit, F. M. Hofhuis, P. M. Guyre, P. J. Capel, J. S. Verbeek, and J. G. van de Winkel. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin.Invest. 1996 97:331.
• Liu, C., J. Goldstein, R. F. Graziano, J. He, J. K. O'Shea, Y. Deo, and P. M. Guyre. FcγRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T-cell epitopes. J. Clin. Invest. 1996 98:2001.
• Graziano, R. F., P. R. Tempest, P. White, T. Keler, Y. Deo, H. Ghebremariam, K. Coleman, L. C. Pfefferkorn, M. W. Fanger, and P.M. Guyre. Construction and characterization of a humanized anti-γ-Ig receptor type I (FcγRI) monoclonal antibody. J. Immunol. 1995 155:4996.
• Guyre, P. M., Graziano R.F., Vance B.A., P. M. Morganelli, and M. W. Fanger. Monoclonal antibodies that bind to distinct epitopes of FcγR are able to trigger receptor function. J. Immunol. 1989 143:1650.
• Gosselin, E. J., K. Wardwell, D. R. Gosselin, N. Alter, J. L. Fisher, and P. M. Guyre. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 1982 149:3477.

APC Targeting: DEC-205

• Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, Nussenzweig MC, Piperno AG, Steinman RM, DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1289-94. Epub 2007 Jan 17.
• Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 2005 65(15):7007-12.
• Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM: In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 2004 199:815-824.
• Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance J. Exp. Med. 2002 196:1627-1638.
• Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC: Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001 194:769-779.
• Guo M, Gong S, Maric S, Misulovin Z, Pack M, Mahnke K, Nussenzweig MC, Steinman RM: A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum. Immunol. 2000 61:729-738.
• Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steinman RM: The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 2000 151:673-684.
• Jiang, W., W.J. Swiggard, C. Heufler, M. Peng, A. Mirza, R.M. Steinman, and M.C. Nussenzweig. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995 375:151-155.
• Witmer-Pack, M.D., W.J. Swiggard, A. Mirza, K. Inaba, and R.M. Steinman. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell. Immunol. 1995 163:157-162.

Human Monoclonal Antibody Programs: CD27

• French, R. R., V. Y. Taraban, G. R. Crowther, T. F. Rowley, J. C. Gray, P. W. Johnson, A. L. Tutt, A. Al-Shamkhani, and M. J. Glennie. 2007. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109:4810-4815.

Human Monoclonal Antibody Programs: CD89

• Deo, Y. M., K. Sundarapandiyan, T. Keler, P. K. Wallace, and R. F. Graziano. 1998. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J. Immunol. 160:1677-1686.
• Kanamaru, Y., S. Pfirsch, M. Aloulou, F. Vrtovsnik, M. Essig, C. Loirat, G. Deschenes, C. Guerin-Marchand, U. Blank, and R. C. Monteiro. 2008. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J. Immunol. 180:2669-2678.

Complement Inhibitor (sCR1, CDX-1135, TP10)

• Pierson, R. N., 3rd, Loyd, J. E., Goodwin, A., Majors, D., Dummer, J. S., Mohacsi, P., Wheeler, A., Bovin, N., Miller, G. G., Olson, S., Johnson, J., Rieben, R., and Azimzadeh, A. (2002) Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy, Transplantation 74, 79-84.
• Lazar HL, Bokesch PM, Van Lenta F, Fitzgerald C, Emmett C, Marsh HC, Jr., Ryan U. 2004. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110 (11 Suppl 1):II274-II279.
• Lazar HL, Keilani T, Fitzgerald CA, et al. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 2007; 116 (11 Suppl): I83.
• Li JS, Jaggers J, Anderson PAW. 2006. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev. Cardiovasc. Ther. 4(5):649-654.
• Li JS, Sanders SP, Perry AE, Stinnett SS, Jaggers J, Bokesch P, Reynolds L, Nassar R, Anderson PA. 2004. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am. Heart J. 147(1):173-80.
• Keshavjee, S., Davis, R. D., Zamora, M. R., de Perrot, M., and Patterson, G. A. (2005) A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings, J. Thorac. Cardiovasc. Surg. 129, 423-428.
• Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. 1995. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J. Amer. Soc. Nephrol. 5(11):1888-1894.
• Kondo, C, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Matsuo .S. 2001. The role of C5a in the development of thrombotic glomerulonephritis in rats. Clin. Exp. Immunol. 124:323-329.
• Morita Y, Nomura A, Yuzawa Nishikawa K, Hotta N, Shimizu F, Matsuo S. 1997. The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 8: 1363-1372.
• Mosley K, Waddington SN, Ebrahim H, Cook T, Cattell V. 1999. Inducible nitric oxide synthase induction in Thy 1 glomerulonephritis is complement and reactive oxygen species dependent. Exp. Nephrol. 7(1):26-34.

Notch Binding Proteins

• Briend, E. Young LL, McKenzie GJ, Tugal T, Ragno S, & Champion BR. Modulation of the notch pathway for immunotherapy. Curr. Opin. Mol. Ther. 2005 7(1): 56-61.
• Dallman, M.J., Smith E, Benson RA & Lamb JR. Notch: control of lymphocyte differentiation in the periphery. Curr. Opin. Immunol. 2005 17(3): 259-66.
• McKenzie, G. J., M. Khan, Briend E, Stallwood Y & Champion B.R. Notch: a unique therapeutic target for immunomodulation. Expert Opin. Ther. Targets. 2005 9(2): 395-410.
• Mckenzie GJ, Young LL, Briend E, Lamb JR, Dallman MJ, & Champion B.R. Notch signalling in the regulation of peripheral T cell function. Semin. Cell Dev. Biol. 2003 14(2):127-34.
• Wong KK, Carpenter MJ, Young LL, Walker SJ, McKenzie G, Rust AJ, Ward G, Packwood L, Wahl K, Delriviere L, Hoyne G, Gibbs P, Champion BR, Lamb JR, Dallman MJ. Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism. J. Clin. Invest. 2003 112(11):1741-50.
• Hoyne GF, Dallman MJ, Champion BR, & Lamb JR. Notch signalling in the regulation of peripheral immunity. Immunol. Rev. 2001 182:215-27.
• Hoyne, Le Roux, Corsin-Jimenez, Tan, Dunne, Forsyth, Dallman, Owen, Ish-Horowicz, Lamb. Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int. Immunol. 2000 12(2):177-85.